Feng Li

US Patent:

7537765, May 26, 2009

Filed:

May 24, 2004

Appl. No.:

10/851637

Inventors:

Karl Salzwedel - Olney MD, US
Feng Li - Gaithersburg MD, US
Carl T. Wild - Gaithersburg MD, US
Graham P. Allaway - Darnestown MD, US
Eric O. Freed - Frederick MD, US

Assignee:

Panacos Pharmaceuticals, Inc. - Gaithersburg MD
The United States of America as represented by the Department of Health and Human Services - Washington DC

International Classification:

A61K 39/00
A61K 39/12
A61K 39/21
A61K 38/00

US Classification:

4241841, 530300, 4241861, 4241871, 4241881

Abstract:

Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

US Patent:

8318425, Nov 27, 2012

Filed:

Jul 6, 2009

Appl. No.:

12/498157

Inventors:

Karl Salzwedel - Olney MD, US
Feng Li - Brookings SD, US
Carl T. Wild - Gaithersburg MD, US
Graham P. Allaway - Darnestown MD, US
Eric O. Freed - Frederick MD, US

Assignee:

The United States of America, as represented by the Secretary, Department & Human Services - Washington DC
Myrexis, Inc. - Salt Lake City UT

International Classification:

C12Q 1/70
C12Q 1/68
A01N 61/00
A01N 57/00
A61K 31/00
A61K 31/66

US Classification:

435 61, 435 5, 435 611, 435 612, 514 1, 514120, 514510

Abstract:

Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to the Gag proteolytic cleavage site rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

US Patent:

20040265320, Dec 30, 2004

Filed:

Jan 29, 2004

Appl. No.:

10/766528

Inventors:

Karl Salzwedel - Olney MD, US
Feng Li - Gaithersburg MD, US
Carl Wild - Gaithersburg MD, US
Graham Allaway - Darnestown MD, US
Eric Freed - Frederick MD, US

International Classification:

A61K039/42

US Classification:

424/160100

Abstract:

Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to the Gag proteolytic cleavage site rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

US Patent:

20080200550, Aug 21, 2008

Filed:

May 24, 2005

Appl. No.:

11/597431

Inventors:

Karl Salzwedel - Olney MD, US
Feng Li - Gaithersburg MD, US
Carl T. Wild - Gaithersburg MD, US
Graham P. Allaway - Darnestown MD, US
Eric O. Freed - Frederick MD, US

Assignee:

V.I. TECHNOLOGIES, INC. - Gaithersburg MD
THE GOV. OF US AS REP. BY THE SEC. DEP. OF HEALTH - Rockville MD

International Classification:

A61K 31/557

US Classification:

514573

Abstract:

Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

US Patent:

20080233559, Sep 25, 2008

Filed:

Dec 21, 2007

Appl. No.:

11/962315

Inventors:

Karl SALZWEDEL - Olney MD, US
Feng Li - Gaithersburg MD, US
Carl T. Wild - Gaithersburg MD, US
Graham P. Allaway - Darnestown MD, US
Eric O. Freed - Frederick MD, US

International Classification:

C12Q 1/70

US Classification:

435 5

Abstract:

Inhibition of HIV-1 replication by disrupting the processing of the viral Gag capsid (CA) protein (p24) from the CA-spacer peptide 1 (SP1) protein precursor (p25) is disclosed. Amino acid sequences containing a mutation in the Gag p25 protein, with the mutation resulting in a decrease in the inhibition of processing of p25 to p24 by dimethylsuccinyl betulinic acid or dimethylsuccinyl betulin, polynucleotides encoding such mutated sequences and antibodies that selectively bind such mutated sequences are also included. Methods of inhibiting, inhibitory compounds and methods of discovering inhibitory compounds that target proteolytic processing of the HIV Gag protein are included. In one embodiment, such compounds inhibit the interaction of the HIV protease enzyme with Gag by binding to Gag rather than to the protease enzyme. In another embodiment, viruses or recombinant proteins that contain mutations in the region of the Gag proteolytic cleavage site can be used in screening assays to identify compounds that target proteolytic processing.

US Patent:

20110166040, Jul 7, 2011

Filed:

May 28, 2009

Appl. No.:

12/995425

Inventors:

James C. Hannis - Vista CA, US
Feng Li - San Diego CA, US
Rangarajan Sampath - San Diego CA, US
Lawrence B. Blyn - Mission Viejo CA, US
Steven A. Hofstadler - Vista CA, US
David J. Ecker - Encinitas CA, US
Mark W. Eshoo - Solana Beach CA, US

Assignee:

IBIS BIOSCIENCES, INC. - Carlsbad CA

International Classification:

C40B 30/10
C12Q 1/68
C40B 30/00
C07H 21/04
H01J 49/26

US Classification:

506 12, 435 612, 506 7, 536 2433, 250281

Abstract:

The present invention relates generally to strain typing of O157:H7, and provides methods, compositions and kits useful for this purpose when combined, for example, with molecular mass or base composition analysis.

US Patent:

20110183345, Jul 28, 2011

Filed:

Sep 30, 2009

Appl. No.:

13/122373

Inventors:

Christian Massire - Carlsbad CA, US
Rachael Kreft - Pittsburgh PA, US
Lawrence B. Blyn - Mission Viejo CA, US
David J. Ecker - Encinitas CA, US
Feng Li - San Diego CA, US
Rangarajan Sampath - San Diego CA, US

Assignee:

Ibis Biosciences, Inc. - Carlsbad CA

International Classification:

C12Q 1/68
H01J 49/26

US Classification:

435 612, 435 615, 250281

Abstract:

The present invention relates generally to the identification of , such as antibiotic resistant , and provides methods, compositions, kits and systems useful for this purpose when combined, for example, with molecular mass or base composition analysis.

US Patent:

20110200997, Aug 18, 2011

Filed:

May 29, 2009

Appl. No.:

12/995427

Inventors:

Sherilynn Manalili Wheeler - Encinitas CA, US
James C. Hannis - Vista CA, US
Feng Li - San Diego CA, US
Raymond Ranken - Encinitas CA, US
Lawrence B. Blyn - Mission Viejo CA, US
David J. Ecker - Encinitas CA, US
Steven A. Hofstadler - Vista CA, US

Assignee:

IBIS Biosciences, Inc. - Carlsbad CA

International Classification:

C12Q 1/68
C12M 1/34

US Classification:

435 611, 435 61, 435 612, 4352872

Abstract:

The present invention relates generally to identification of enteric bacterial pathogens, and provides methods, compositions and kits useful for this purpose when combined, for example, with molecular mass or base composition analysis.